INOMAX

Země: Singapur

Jazyk: angličtina

Zdroj: HSA (Health Sciences Authority)

Aktivní složka:

Nitric Oxide

Dostupné s:

BIOMEDICAL STRATEGY CONSULTANTS PTE LTD

ATC kód:

R07AX01

Dávkování:

800ppm

Léková forma:

GAS

Podání:

RESPIRATORY (INHALATION)

Druh předpisu:

Prescription Only

Výrobce:

INO Therapeutics

Datum autorizace:

2007-09-20

Informace pro uživatele

 
Page 1 of 9

INOMAX® (NITRIC OXIDE) FOR INHALATION   
800 PPM (PARTS PER MILLION) 

DESCRIPTION_ _
INOMAX (nitric oxide gas) is a drug administered by inhalation.
 Nitric oxide, the active 
substance in INOmax, is a pulmonary vasodilator.  INOmax is a
gaseous blend of nitric oxide  
and nitrogen (0.08% and 99.92%, respectively for 800 ppm).  INOmax is
supplied in aluminum 
cylinders as a compressed gas under high pressure (2000 pounds per
square inch gauge [psig]).   

The structural formula of nitric oxide (NO) is shown below: 

N O

CLINICAL PHARMACOLOGY_ _
Nitric oxide is a compound produced by many cells of the body.   It
relaxes vascular smooth 
muscle by binding to the heme moiety of cytosolic guanylate cyclase,
activating guanylate 
cyclase and increasing intracellular levels of cyclic guanosine
3’,5’-monophosphate, which then 
leads to vasodilation. When inhaled, nitric oxide produces pulmonary
vasodilation.  

INOmax

appears to increase the partial pressure of arterial oxygen (PaO2) by
 dilating 
pulmonary vessels in better ventilated areas of the lung,
redistributing pulmonary blood flow 
away from lung regions with low ventilation/perfusion (V/Q) ratios
toward regions with normal 
ratios. 

EFFECTS ON PULMONARY VASCULAR TONE IN PPHN:  Persistent pulmonary
hypertension of the 
newborn (PPHN) occurs as a primary developmental defect or as a
condition secondary to other 
diseases such as meconium aspiration syndrome (MAS), pneumonia,
sepsis, hyaline membrane 
disease, congenital diaphragmatic hernia (CDH), and pulmonary
hypoplasia.  In these states, 
pulmonary vascular resistance (PVR) is high, which results in
hypoxemia secondary to right-to-
left shunting of blood through the patent ductus arteriosus and
foramen ovale.  In neonates with 
PPHN, INOmax improves oxygenation (as indicated by significant
increases in PaO2).  

PHARMACOKINETICS 
The pharmacokinetics of nitric oxide has been studied in adults._ _
UPTAKE AND DISTRIBU